Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 6Thoracic 3Gynecologic 3Genitourinary 3Gastrointestinal 3Sarcoma 2Lymphoid 2Head & Neck 2CNS 2Breast 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Wilms Tumor 7Neuroblastoma 7Hepatoblastoma 7Glioma 7Rhabdoid Tumor 6Osteosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Multiple Myeloma 6Medulloblastoma 6Lymphoma 6Leukemia, Myeloid, Acute 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma 5Rhabdomyosarcoma 5Lymphoma, Large B-Cell, Diffuse 5Central Nervous System Neoplasms 5Sarcoma, Ewing 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Burkitt Lymphoma 4Lymphoma, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Mycosis Fungoides 2Melanoma 2

Interventions

pembrolizumab 14Nivolumab 9Specimen Handling 4Magnetic Resonance Spectroscopy 4fludarabine 3atezolizumab 3Ipilimumab 3Drug Therapy 3Cyclophosphamide 3epacadostat 2entrectinib 2durvalumab 2X-Rays 2Sirolimus 2Radiotherapy 2Radiation 2Methods 2Interleukin-2 2Injections 2CTLA-4 Antigen 2Blood Specimen Collection 2Biopsy 2zimberelimab 1vocimagene amiretrorepvec 1varlilumab 1utomilumab 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × X-Rays × Lymphoid × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡